Oxaliplatin

Catalog No.S1224 Synonyms: L-OHP

Oxaliplatin Chemical Structure

Molecular Weight(MW): 397.29

Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.

Size Price Stock Quantity  
USD 70 In stock
USD 120 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Immunocytochemical staining of SW620 (metastatic) cells after treatment with 10 uM oxaliplatin (F) or 10 uM ginsenosides 20(S)-Rg 3 (G) and negative staining (H). Cells demonstrated differential expression of histone H4.

    J Proteomics 2014 10.1016/j.jprot.2014.10.009. Oxaliplatin purchased from Selleck.

    PDT and oxaliplatin combination treatment. A) Bar graph showing response (total volume of residual viale nodules normalized to no treatment control) to PDT treatmen (2.5 J/cm2), oxaliplatin treatment (10 μM), and PDT followed by oxaliplatin at the same doses. The dramatic enhancement, beyond the additive effect of the two modalities independently suggests there may be a synergistic interaction. B) A representative region from a culture stained with calcein AM and ethidium bromide following treatment with the PDT + oxaliplatin combination shows relatively small pockets of viable disease and many dead relative to untreated cultures.

    Optical Methods for Tumor Treatment and Detection 2013 10.1117/12.2010730. Oxaliplatin purchased from Selleck.

  •  

    Growth inhibitory effects of Oxaliplatin in human pancreatic cancer cells. MiaPaCa-2 cells were plated in triplicates into 48-well plates at a density of 10,000 cells/ml. After 24 hours, complete culture medium was changed into fresh low-serum-containing medium (1% FBS) containing DMSO (control) or indicated doses of Oxaliplatin (Selleckchem). Cell viability 72 hours after treatment was determined by AlamarBlue assay (Invitrogen) according to manufacturer's instructions. Results are expressed as percentages of control, which was arbitrarily assigned 100% viability, and represented as the mean ± standard deviation (SD) of the tripicate wells. 

    2013 Dr. Edita Aksamitiene from Thomas Jefferson University. Oxaliplatin purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.
Targets
DNA synthesis [1]
(RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, HT-144 cells)
In vitro

The main mechanism of action of Oxaliplatin is mediated through the formation of DNA–adducts. Oxaliplatin induces primary and secondary DNA lesions that lead to cell apoptosis. [1] Oxaliplatin is active against human melanoma cell lines C32 and G361 with IC50 of 0.98 mM and 0.14 mM, respectively. [2] Oxaliplatin effectively inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HKESC-2 NYnueJZGS3m2b4TvfIlkcXS7IFHzd4F6 MlHlNQKBmzF4MNMg{txO NXzFXmZ1PDkEoHi= M2rvRWlEPTB;NT64xsDDucLiMD61JO69VQ>? MWWyOlQ4PDZ7Mx?=
CaES-17 NVrkeFh4S3m2b4TvfIlkcXS7IFHzd4F6 MofENQKBmzF4MNMg{txO NUi0PINTPDkEoHi= MXrJR|UxRTVwNdMgxtHDqDBwMjFOwG0> NHSwbpEzPjR5NE[5Ny=>
SW480 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjESmk1QCCqwrC= MWrJR|UxRTFwOEeg{txO NFe2fWQzPjJ4OUe1PS=>
HCT116 NHfkTpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFj1dpQ1QCCqwrC= MWjJR|UxRTFzLki2JO69VQ>? MVuyOlI3QTd3OR?=
LoVo MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX20PEBpyqB? NFXsUXlKSzVyPUm0Mlg{KM7:TR?= NFTPVJgzPjJ4OUe1PS=>
SK-BR-3 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7LTWM2OD1|MT6wJOKyKDBwMTFOwG0> NVS1OZpiOjZ{MUG1PVE>
MCF-7 NVjHXHF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTF3LkSgxtEhOC5|IN88US=> NGW1fFEzPjJzMUW5NS=>
MDA-MB-231 M4L5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrITXdTUUN3ME2yN{4yKMLzIECuNUDPxE1? NYD1VY1IOjZ{MUG1PVE>
HCT116 p53+/+ M1rkdmZ2dmO2aX;uJGF{e2G7 MmLpNU82KM7:TR?= MViyOE81QCCq NYn4RZAycW6mdXPld{B1emGwc3PybZB1cW:wYXygdoVxemW|c3nvckBw\iCGVWStUi=> MWSyOlIxQDV{Mx?=
LoVo  NFrtS|lHfW6ldHnvckBCe3OjeR?= NXzpcm5[OS93IN88US=> MUiyOE81QCCq NFPqSYxqdmS3Y3XzJJRz[W6|Y4LpdJRqd26jbDDy[ZBz\XO|aX;uJI9nKESXVD3O MXeyOlIxQDV{Mx?=
SNU-398 M13vOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zDRWlEPTB;Nj61xsDDucLiMT6xJO69VQ>? NXXjeYJuOjZzNkC0Nlk>
Hep-G2 MkXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrtUIJ{UUN3ME2xN{4yyqEEsdMgNU43KM7:TR?= NGrY[oUzPjF4MESyPS=>
SNU-475 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jscmlEPTExvK6zNEDPxE1? MV6yOlE3ODR{OR?=
SNU-387 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTJ3wrFCteKhOi55IN88US=> NFfiXoozPjF4MESyPS=>
HT29 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwOElCpOKyyqByLkKg{txO MnT2NlYyPDh3OU[=
HCT116 M37q[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEH6VlJKSzVyPUCuOFHDqMLzwrCwMlAzKM7:TR?= NEXUbVgzPjF2OEW5Oi=>
PA-1 NFu3b4RE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NYXJPIRoOC1{MDFOwG0> NHW1VHQzPC92ODDo M4G1OYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[UBidmRiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MkjHNlYyOzh4N{G=
OVCAR-5 M3fmWGNmdGxiVnnhZoltcXS7IFHzd4F6 NVTzfFdXOC14MDFOwG0> NUi3OGhPOjRxNEivO|IhcA>? NV\1O2xpcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M3vjNlI3OTN6Nkex
SK-OV-3 NGXvbI1E\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3PFPFAuOTByIN88US=> M4KwNFI1NzR6L{eyJIg> NYDrOHZKcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NHzTVWwzPjF|OE[3NS=>
PA-1 M3r2NWZ2dmO2aX;uJGF{e2G7 NIHycXUyOCEQvF5CpC=> M4m2RlI1cA>? Ml;ZeJJq\2encnXzJJRp\SCycn;keYN1cW:wIH;mJJR6eGViSTDJSm5{KGGwZDDjbIVud2urbnXz NW\oRXJ{OjZzM{i2O|E>
OVCAR-5 NHnvdWxHfW6ldHnvckBCe3OjeR?= NILSZ3g{OCEQvF2= M3PhdlQ5cA>? MkjreJJq\2encnXzJJRp\SCycn;keYN1cW:wIH;mJJR6eGViSTDJSm5{KGGwZDDjbIVud2urbnXz M{fFXlI3OTN6Nkex
SK-OV-3 NYfq[G9nTnWwY4Tpc44hSXO|YYm= NWfkUIs6PTBizszN MmjjPVYhcA>? NILucZB1emmpZ3Xy[ZMhfGinIIDyc4R2[3Srb36gc4YhfHmyZTDJJGlHVnNiYX7kJINp\W2xa3nu[ZM> MojBNlYyOzh4N{G=
PA-1 NHHxeZRHfW6ldHnvckBCe3OjeR?= Mnv5NVAh|ryPwrC= MWm0PIg> MWX1dE1z\We3bHH0[ZMhfGinIIP0doV{eyCuaXfhcoR{KG[xcjDOT{Bk\WyuLXHjeIl3[XSrbnegdoVk\XC2b4LzJIFv\CCWUlHJUEBz\WOncITvdpM> MkfxNlYyOzh4N{G=
OVCAR-5 NYXjV|lrTnWwY4Tpc44hSXO|YYm= MUezNEDPxE1? M2XZOVQ5cA>? NVrye|lmfXBvcnXneYxifGW|IITo[UB{fHKnc4OgcIlo[W6mczDmc5IhVktiY3XscE1i[3SrdnH0bY5oKHKnY3XweI9zeyCjbnSgWHJCUUxicnXj[ZB1d3K| MU[yOlE{QDZ5MR?=
SK-OV-3 NFi0XVhHfW6ldHnvckBCe3OjeR?= MoixOVAh|ryP MUK5OkBp MWP1dE1z\We3bHH0[ZMhfGinIIP0doV{eyCuaXfhcoR{KG[xcjDOT{Bk\WyuLXHjeIl3[XSrbnegdoVk\XC2b4LzJIFv\CCWUlHJUEBz\WOncITvdpM> NFi5ZlEzPjF|OE[3NS=>
PA-1 MVPGeY5kfGmxbjDBd5NigQ>? MVWxNEDPxE4EoB?= MX[yOIg> Mm[1dJJwdW:2ZYOgd4Vve2m2aY\peJkhd2Zib4\hdolidiClYYLjbY5wdWFidH:gUmsh[2WubD3t[YRq[XSnZDDjfZRwdHm|aYO= Mo\ENlYyOzh4N{G=
OVCAR-5 NXnCUJI3TnWwY4Tpc44hSXO|YYm= MWWyNEDPxE4EoB?= MVmyOIg> NHXHeXZxem:vb4Tld{B{\W6|aYTpeol1gSCxZjDveoFzcWGwIHPhdoNqdm:vYTD0c{BPUyClZXzsMY1m\GmjdHXkJIN6fG:ueYPpdy=> Ml;uNlYyOzh4N{G=
SK-OV-3 MWTGeY5kfGmxbjDBd5NigQ>? NISyc|g2OCEQvF5CpC=> MlPXOFghcMLi MnfBdJJwdW:2ZYOgd4Vve2m2aY\peJkhd2Zib4\hdolidiClYYLjbY5wdWFidH:gUmsh[2WubD3t[YRq[XSnZDDjfZRwdHm|aYO= M4i4OFI3OTN6Nkex
CT26  MXPGeY5kfGmxbjDBd5NigQ>? NYLmZpZ5PCCvTR?= MYC0PEBpyqB? MlHUbY5lfWOnczDheZRweGijZ4m= NGn4bGczPjF|N{CxNi=>
CT26  MW\GeY5kfGmxbjDBd5NigQ>? M4ju[FQhdU1? M3TO[VQ5KGkEoB?= NHe0NpFqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wy|IH;mJIF2fG:yaHHnfU1z\WyjdHXkJJBzd3SnaX7zMEB{fWOqIHHzJGxEOy2LSTygRoVkdGmwMTDhcoQhSVSJNR?= M4DXb|I3OTN5MEGy
CT26  NX3BcGpDS2WubDDWbYFjcWyrdImgRZN{[Xl? NHjTc281KG2P NXG5PGFuPDhiaNMg NUfjfJQ6\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJRwKDV|LkKl M2HWPFI3OTN5MEGy
BE MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rxTWlEPTB;Mz6zN{DPxE1? M4HTdVI3ODJ|MEi1
Colo205 MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfSTWM2OD1|LkOzJO69VQ>? MmGxNlYxOjNyOEW=
DLD1 MnXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHsc4w6UUN3ME2yMlAyKM7:TR?= NYnPUIJNOjZyMkOwPFU>
HT29 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\jcJRKSzVyPUKuOlkh|ryP NWXVeIJ1OjZyMkOwPFU>
HCT15 MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTFwNEOg{txO NHHJV4IzPjB{M{C4OS=>
HCT116 M1W0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3z1WWlEPTB;MT6wOEDPxE1? NYi0WGVxOjZyMkOwPFU>
HCT116p53- M2r5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTFwMEig{txO NF7vS3gzPjB{M{C4OS=>
KM12 NUDsTogzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXqyeplpUUN3ME20MlM4KM7:TR?= M3W2d|I3ODJ|MEi1
LoVo MkXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rDOWlEPTB;MT6yJO69VQ>? MlXmNlYxOjNyOEW=
RKO MnOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTFwMkOg{txO Ml3kNlYxOjNyOEW=
SW480 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rjZmlEPTB;Mj64OkDPxE1? NYi0fVZbOjZyMkOwPFU>
SW620 Ml;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTNwNkig{txO M2rP[|I3ODJ|MEi1
MC38 MlrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzTTWM2OD1{MzFOwG0hyrFiMh?= MlLzNlYxODRyOES=
HT29 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTZ|IN88UUDDuSBzOB?= NFHjNWszPjByNEC4OC=>
DLD-1 NXW2N2Z6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTVTWM2OD1|Mj6yJO69VQ>? MorENlYxODNyOEW=
HT-29 NF;De3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPZTWM2OD1|NT62JO69VQ>? NFK3SHQzPjByM{C4OS=>
SiHa NVSxSIdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LZcWlEPTB;MD64JOKyKDBwMTFOwG0> MXSyOVgxOTByNx?=
S3 NXvLcpZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmL0TWM2OD13Mz61JOKyKDFwNTFOwG0> MoX1NlU5ODFyMEe=
AGS MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTFyLk[g{txO NEnSRo8zPTd6OUC1Oy=>
MKN-45 NH3ub3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NET0b4RKSzVyPUG0MlAh|ryP MoX5NlU4QDlyNUe=
TMK-1 NWHienE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\WTWM2OD1{Mj62JO69VQ>? M3;MdFI2Pzh7MEW3
SCM-1 NWn5emZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[2dpVGUUN3ME2xO{42KM7:TR?= MoryNlU4QDlyNUe=
HCT-15 MnjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRThwNkSg{txO NVTGO2dbOjV5NkG0O|k>
DiFi MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITsS2RKSzVyPUGwMlk2KM7:TR?= MYmyOVc3OTR5OR?=
DLD-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRThwNkWg{txO MYGyOVc3OTR5OR?=
COLO-320DM NX;OU5Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTVwM{ig{txO Mn;vNlU4PjF2N{m=
SNU-175 MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3u5Z2lEPTB;MT61NUDPxE1? M1vVfFI2PzZzNEe5
HT-29 MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHJTWM2OD13LkKyJO69VQ>? MX6yOVc3OTR5OR?=
SW620 NFnBdWhHfW6ldHnvckBCe3OjeR?= NYLSUXhCOTEkgJpCuYcwdWx? Mke5NlTjiImq NYPqO4MxcW6lcnXhd4V{KEyFMz3JTUBi[2O3bYXsZZRqd25iYX7kJIRm[3KnYYPld{BRPjJiZYjwdoV{e2mxbh?= MXuyOVc1QTR{MB?=
SW480 MXvGeY5kfGmxbjDBd5NigQ>? M{PETVEx6oDLwsXnM41t NHnnb4IzPOLCiXi= Mlv5bY5kemWjc3XzJGxEOy2LSTDhZ4N2dXWuYYTpc44h[W6mIHTlZ5Jm[XOnczDQOlIh\XiycnXzd4lwdg>? NFHjSW0zPTd2OUSyNC=>
SW620 NWSxSYxiTnWwY4Tpc44hSXO|YYm= NEftcJEyOOLCidM1[{9udA>? NW\MepNjOjUkgJno NUPSOZBu\W6qYX7j[ZMh[2WubIXsZZIh[XW2b4DoZYdq[yCobIX4 NHvSR4EzPTd2OUSyNC=>
SW480 NXraNHdpTnWwY4Tpc44hSXO|YYm= NIHyPWUyOOLCidM1[{9udA>? MoWwNlTjiImq NHzJVlJmdmijbnPld{Bk\WyudXzhdkBifXSxcHjh[4lkKG[udYi= NFSzOHMzPTd2OUSyNC=>
A549 NID4WmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PudGlEPTB;NT64JOKyKDBwNjFOwG0> M3;CTVI2PjJ3MkSz
A549/CDDP NEHQN4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXzc3FsUUN3ME2xPE43KMLzIEGuNkDPxE1? M{X6dFI2PjJ3MkSz
Panc-1 MmriR4VtdCCYaXHibYxqfHliQYPzZZk> NIPnSoczPS93MDFOwG0> MorTNlQwPDhiaB?= NEDtT2pqdmirYnn0d{Bxem:uaX\ldoF1cW:wIH;mJHBEKGOnbHzzJIlvKGFic4nu[ZJocXO2aXOgcYFvdmW{IHPvcYJqdmWmIIfpeIghX0F? MmHWNlU1PDR7MUS=
MIAPaCa-2 M3;K[2NmdGxiVnnhZoltcXS7IFHzd4F6 M3z1bVI2NzVyIN88US=> M{\lUVI1NzR6IHi= MonFbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC M2LuN|I2PDR2OUG0
SW1990 MnHKR4VtdCCYaXHibYxqfHliQYPzZZk> MUGyOU82OCEQvF2= MmPKNlQwPDhiaB?= NUnte4d[cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDv[kBRSyClZXzsd{BqdiCjIIP5coVz\2m|dHnjJI1idm6ncjDjc41jcW6nZDD3bZRpKFeD NV\rWHBqOjV2NES5NVQ>
HPDE NHzCXphE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MX:yOU82OCEQvF2= M3H6XFI1NzR6IHi= NWnyNWlIcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDv[kBRSyClZXzsd{BqdiCjIIP5coVz\2m|dHnjJI1idm6ncjDjc41jcW6nZDD3bZRpKFeD MnPyNlU1PDR7MUS=
Panc-1 NHLHO4tCeG:ydH;zbZMhSXO|YYm= NHvSTmIzPeLCidM1US=> NVqyb2M4OjRiaB?= NYfhXJJ6cW6mdXPld{BieG:ydH;zbZMhcW5iYTDzfY5memerc4TpZ{Bu[W6wZYKgZ49u[mmwZXSge4l1cCCZQR?= Ml7aNlU1PDR7MUS=
MIAPaCa-2 NYO2c4tzSXCxcITvd4l{KEG|c3H5 MonGNlXjiIoEtV2= MoG2NlQhcA>? Mn2wbY5lfWOnczDhdI9xfG:|aYOgbY4h[SC|eX7ldodqe3SrYzDtZY5v\XJiY3;tZolv\WRid3n0bEBYSQ>? Ml7QNlU1PDR7MUS=
Panc-1 MoX5SpVv[3Srb36gRZN{[Xl? NWXUb|VGOjYkgJpCuW0> NV\2bng{OjRxNEigbC=> MVfpcoR2[2W|IHPs[YF3[WenIH;mJHBCWlBuIHPhd5Bie2VvOTygZ4F{eGG|ZT24JIFv\CClYYPwZZNmNTQEoB?= NUXJXmFmOjV2NES5NVQ>
MIAPaCa-2 MXnGeY5kfGmxbjDBd5NigQ>? Ml3yNlXjiIoEtV2= M4XlTlI1NzR6IHi= NWPqPYpVcW6mdXPld{BkdGWjdnHn[UBw\iCSQWLQMEBk[XOyYYPlMVktKGOjc4Dhd4UuQCCjbnSgZ4F{eGG|ZT2zxsA> NYXvbo1DOjV2NES5NVQ>
SW480 NITX[3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXm3NkBpyqB? MojmTWM2OD1zMD63xtEzNjJ4INM1[{9uVA>? NXjLcHR3OjV|NkC2N|E>
HCT116  NILCUm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUi3NkBpyqB? MYXJR|UxRTZwMkRCtVAvPzViwsXnM41N MoT1NlU{PjB4M{G=
COC1 MmL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkO2TWM2OD12Nj6yNOKhyrIEoEOuNVQh|ryP MnrONlU{ODd2NEi=
SGC7901 NHTaN|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17PUWlEPTB;MkGuO|PDqMLzwrCzMlA5KM7:TR?= NGrh[|AzPTNyN{S0PC=>
A549 M2rXVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkK0TWM2OD13MT6wPOKhyrIEoEGwMlk3KM7:TR?= M17wZlI2OzB5NES4
HepG2 M2jLO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDTcItKSzVyPUG0MlI1yqEEsdMgNU45OiEQvF2= NIPP[5czPTNyN{S0PC=>
MCF-7 NF7aXVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULC[JQ{UUN3ME2xOE4zPMLiwsJCpFEvQDJizszN MmjINlU{ODd2NEi=
HCT-116 NF;SdY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWi0XWJnUUN3ME22MlI1yqEEsdMgNk46PyEQvF2= NFXkbJQzPTNyN{S0PC=>
HT-29 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHYTWM2OD53MDFOwG0> NHf1bFUzPTNyN{S0PC=>
HEK293 Mn[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDPO5R4UUN3ME24MlgzyqEEsdMgOU42QSEQvF2= NGjX[|czPTNyN{S0PC=>
HUVEC M4qyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXPdpZrUUN3ME2xNU4{OMLiwsJCpFEvODJizszN MnHTNlU{ODd2NEi=
SW480 NGrGcJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYqxxsDPxE1? Mom5NE04OiCq NGTDRZdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJJRqdWViZHXw[Y5l\W62IH3hco5meg>? NV;BT5NKOjR7OUe0OVE>
HT-29 M4\UeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTzSoNNOcLizszN NFOyfVkxNTd{IHi= MY\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> MorrNlQ6QTd2NUG=
HCT116 M2HQcmZ2dmO2aX;uJGF{e2G7 NX[5O2cyOi93INM1US=> NWP6WVZiOjRxNEigbC=> Mljyd5VxeHKnc4Pld{B{fXK4aY\pckBuWk6DIHX4dJJme3Orb36= MWCyOFc3OTRzMR?=
SW480  MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjwR3M1QCCqwrC= Mk\3TWM2OD1{MD64JJVoN22O NF\NT2EzPDd{ME[3OS=>
SW620 M3rmR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEe4PIgyOC15MDDt[{9N M3T2SVI1NzR6L{eyJIg> M{DUd4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M1vyUlI1PjR4M{C1
Caco2  NH;ubHdHfW6ldHnvckBCe3OjeR?= MmOzN|DDqM7:TR?= MU[yOEBp NH\VeFVFVVOR M2[0Solv\HWlZYOgeIhmKGW6cILld5Nqd25ib3[gTG8uOSxiQVvSNWMtKGGwZDDOVW8y NYOwV3lmOjR3NU[0NVU>
Caco2  NFvJNY1HfW6ldHnvckBCe3OjeR?= NVXPUJZ3Oy9zMD:zNEDPxE1? MlnxNVYhcA>? M2DBOWROW09? NHPXNnNqdmO{ZXHz[ZMhfGinIH3SUmEhdGW4ZXzzJI9nyqCDS2KxR|EtKE6TT{GsJGhQNTFuIF3SVFItyqCjbnTNVnA{yqCmb4PlMYRmeGWwZHXueIx6 M1jxV|I1PTV4NEG1
Caco2 M17yVGZ2dmO2aX;uJGF{e2G7 NULH[4VSOzBxMUCwxsDPxE1? MXKxOuKhcA>? MnvzSG1UVw>? NWnTZXFO[WO2aY\heIV{KE6{ZkK= NGPaXWgzPDV3NkSxOS=>

... Click to View More Cell Line Experimental Data

In vivo A weekly i.p. injection of Oxaliplatin at 10 mg/kg to nude mice bearing hepatocellular HCCLM3 tumors significantly reduces tumor volume and apoptotic index. [6] Oxaliplatin (5mg/kg, i.v. on days 1, 5 and 9) is active on T-leukemia-lymphoma L40 AKR with T/C of 1.77. Oxaliplatin is also efficient on intracerebrally grafted L1210 leukemia, MA 16-C xenografts, B16 melanoma xenografts, Lewis lung xenografts and C26 colon carcinoma xenografts. [7] Oxaliplatin induces impairment of retrograde neuronal transport in mice. [8]

Protocol

Cell Research:[4]
+ Expand
  • Cell lines: RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 and HT-144 cell lines
  • Concentrations: ~100 μM
  • Incubation Time: 48 hours
  • Method: The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO2 and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 103 cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: Human hepatocellular carcinoma xenografts HCCLM3
  • Formulation: Water solution
  • Dosages: 10 mg/kg
  • Administration: A weekly i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro Water 3 mg/mL warmed (7.55 mM)
Ethanol 0.01 mg/mL (0.02 mM)
DMF Insoluble
In vivo Add solvents individually and in order:
5% glucose (with warming)
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 397.29
Formula

C8H14N2O4Pt

CAS No. 61825-94-3
Storage powder
in solvent
Synonyms L-OHP

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01928290 Recruiting Stomach Neoplasms|Esophageal Neoplasms Washington University School of Medicine November 8, 2013 Phase 2
NCT03050814 Not yet recruiting Colorectal Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 3, 2017 Phase 2
NCT02997228 Not yet recruiting Colorectal Adenocarcinoma|High-Frequency Microsatellite Instability|Stage IV Colorectal Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer National Cancer Institute (NCI) November 2017 Phase 3
NCT02912559 Not yet recruiting Colon Adenocarcinoma|DNA Repair Disorder|Lynch Syndrome|Microsatellite Instability|Stage IIIA Colon Cancer|Stage IIIB Colon Cancer|Stage IIIC Colon Cancer National Cancer Institute (NCI) September 2017 Phase 3
NCT03043729 Not yet recruiting Rectal Cancer|Rectosigmoid Cancer AIO-Studien-gGmbH|Institut für Klinisch-Onkologische Forschung (IKF) Frankfurt|Sanofi February 2017 Phase 2
NCT03000374 Not yet recruiting Rectal Cancer Grupo Espanol Multidisciplinario del Cancer Digestivo|Pivotal S.L.|Amgen February 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is it ok to dissolve Oxaliplatin in DMSO?

  • Answer:

    Even though cis-platin is soluble in DMSO, the use of DMSO to dissolve cis– or trans-diamminedichloroplatinum (DDP) in biological studies is strongly discouraged. The DMSO inserts itself into the ligand and inactivates platin-containing compounds. DMF is a much better choice than DMSO.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Oxaliplatin | Oxaliplatin supplier | purchase Oxaliplatin | Oxaliplatin cost | Oxaliplatin manufacturer | order Oxaliplatin | Oxaliplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID